OncoGenex Pharmaceuticals Inc. (Nasdaq: OGXI) reported that a subpopulation of men in a Phase 3 AFFINITY trial with custirsen experienced no improvement sending the stock price tumbling 99 cents to close at $1.63.
Disappointing subgroup results for OncoGenex Pharmaceuticals
December 02, 2015 at 19:07 PM EST